The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estimated to be approaching 200 million people 1 . Current therapy relies upon a combination of pegylated interferon-a and ribavirin, a poorly tolerated regimen typically associated with less than 50% sustained virological response rate in those infected with genotype 1 virus 2,3 . The development of direct-acting antiviral agents to treat HCV has focused predominantly on inhibitors of the viral enzymes NS3 protease and the RNA-dependent RNA polymerase NS5B 4 . Here we describe the profile of BMS-790052, a small molecule inhibitor of the HCV NS5A protein that exhibits picomolar half-maximum effective concentrations (EC 50 ) towards replicons expressing a broad range of HCV genotypes and the JFH-1 genotype 2a infectious virus in cell culture. In a phase I clinical trial in patients chronically infected with HCV, administration of a single 100-mg dose of BMS-790052 was associated with a 3.3 log 10 reduction in mean viral load measured 24 h post-dose that was sustained for an additional 120 h in two patients infected with genotype 1b virus. Genotypic analysis of samples taken at baseline, 24 and 144 h post-dose revealed that the major HCV variants observed had substitutions at amino-acid positions identified using the in vitro replicon system. These results provide the first clinical validation of an inhibitor of HCV NS5A, a protein with no known enzymatic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations of HCV inhibitors.
The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estimated to be approaching 200 million people 1 . Current therapy relies upon a combination of pegylated interferon-a and ribavirin, a poorly tolerated regimen typically associated with less than 50% sustained virological response rate in those infected with genotype 1 virus 2,3 . The development of direct-acting antiviral agents to treat HCV has focused predominantly on inhibitors of the viral enzymes NS3 protease and the RNA-dependent RNA polymerase NS5B 4 . Here we describe the profile of BMS-790052, a small molecule inhibitor of the HCV NS5A protein that exhibits picomolar half-maximum effective concentrations (EC 50 ) towards replicons expressing a broad range of HCV genotypes and the JFH-1 genotype 2a infectious virus in cell culture. In a phase I clinical trial in patients chronically infected with HCV, administration of a single 100-mg dose of BMS-790052 was associated with a 3.3 log 10 reduction in mean viral load measured 24 h post-dose that was sustained for an additional 120 h in two patients infected with genotype 1b virus. Genotypic analysis of samples taken at baseline, 24 and 144 h post-dose revealed that the major HCV variants observed had substitutions at amino-acid positions identified using the in vitro replicon system. These results provide the first clinical validation of an inhibitor of HCV NS5A, a protein with no known enzymatic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations of HCV inhibitors.
We designed a mechanistically unbiased approach based on chemical genetics to identify chemical starting points for interfering with HCV replication. Our differentiating strategy centred on the identification of compounds functionally distinct from those acting on the traditional targets of antiviral research in this field, the NS3 protease and the NS5B RNA-dependent RNA polymerase [5] [6] [7] . Using a Con-1 genotype 1b replicon replicating in Huh-7 liver cells 8 , we screened over one million compounds from the Bristol-Myers Squibb proprietary collection in high throughput mode. We used a dual assay format that simultaneously evaluated replication of the related flavivirus bovine viral diarrhoea virus (BVDV) and host cell cytotoxicity as an efficient means of preliminarily eliminating compounds without specificity for HCV 9 . Active inhibitors were further triaged by evaluation in biochemical assays for NS3 protease, NS3 helicase and NS5B polymerase in addition to screening against a panel of unrelated viruses. The iminothiazolidinone BMS-858 ( Fig. 1 ) emerged as a weak but, more importantly, specific inhibitor of HCV RNA replication (EC 50 5 0.57 mM, halfmaximum cytotoxic concentration (CC 50 ) 5 .50 mM) for which resistance was mapped to a tyrosine to histidine substitution at residue 93 in the NS5A protein (Y93H or Y2065H in the HCV polyprotein) 10 .
BMS-858 formed the basis of an extensive series of chemical refinements that focused on improving antiviral potency, broadening inhibitory activity to encompass the HCV 1a genotype, and optimizing for oral bioavailability and sustained pharmacokinetic properties. After defining symmetry as an important contributor to antiviral activity 10 , a discovery that preceded the disclosure of structural information (see below), we subsequently identified BMS-790052 ( Fig. 1 ) as a development candidate for advancement into clinical trials 11 . (The studies leading to the identification of BMS-790052 and its preclinical profiling will be the subject of a series of separate publications.) This compound is the most potent HCV replication inhibitor reported so far, with mean EC 50 values of 50 and 9 pM against genotype 1a and 1b replicons, respectively (data summarized in Table 1 ). BMS-790052 displays a therapeutic index (CC 50 /EC 50 ) of at least 100,000 in vitro and is inactive towards a panel of 10 RNA and DNA viruses, with EC 50 values greater than 10 mM, which confirms specificity for HCV (Supplementary Tables 1  and 2 ). Upon further analysis, we determined that the inhibitory activity of BMS-790052 maps to the first 100 amino acids of HCV NS5A (see below). The antiviral activity of the compound towards additional genotypes was assessed by using replication-competent 1a 12 or 1b replicons to construct hybrids in which the entire NS5A coding region or the first 100 amino acids of NS5A from genotypes 2a, 3a, 4a and 5a replaced the corresponding sequence of the parent replicon 13 . This approach has been validated using genotype-specific inhibitors of HCV NS5A 10 . As summarized in Table 1 , BMS-790052 demonstrates potent inhibitory activity towards all genotypes tested, with EC 50 values ranging from 9 to 146 pM. In combination studies, BMS-790052 displayed additive-to-synergistic effects with interferon-a/ ribavirin, an inhibitor of NS3 protease (ITMN-191), and both nucleoside and allosteric inhibitors of NS5B polymerase, which is indicative of the potential of this molecule as a candidate for combination therapy with other HCV therapeutic agents (data summarized in Table 2 ) (Supplementary Tables 3-7) . More significantly, BMS-790052 is a potent inhibitor of the JFH-1 genotype 2a infectious virus that replicates in cell culture (EC 50 5 28 pM), an assay considered to be a more biologically relevant in vitro cell culture system 14 . In addition, BMS-790052 displayed similar potency in Huh-7, HeLa and HEK293T cells (Supplementary Table 8 ), demonstrating that the function(s) of NS5A inhibited by BMS-790052 is (are) highly conserved in different cellular environments.
To characterize the resistance profile of BMS-790052, genotype 1a and 1b replicon cells were maintained in the presence of the drug at concentrations 5-20 times above the respective EC 50 values. Direct sequencing of individual clones from both 1a-and 1b-resistant cells revealed multiple changes in the first 100 amino acids of NS5A that, when individually introduced into a wild-type replicon background, displayed a resistant phenotype to BMS-790052. Table 3 shows the results of the contribution of these substitutions to resistance in transient replication assays, which were used to ensure that the observed resistant phenotype was caused by inhibitor-induced substitution(s). For genotype 1b, L31V and Y93H were identified as the major resistant variants whereas changes were observed at residues M28 and Q30 of genotype 1a in addition to substitutions at residues L31 and Y93. In general, substitutions in genotype 1b NS5A confer only modest effects on the potency of BMS-790052 whereas substitutions in genotype 1a NS5A are associated with much higher levels of resistance in the replicon system. The most resistant 1a variant, L31V, is inhibited in vitro with an EC 50 of approximately 20 nM, a plasma concentration that we have shown is readily achievable in humans after oral dosing (see below), which indicates that single-point substitutions should be suppressed in vivo. Notably, many of these resistant variants display reduced fitness in vitro and none are recorded as major species in the HCV sequence database, which suggests that natural selection prevents them from having a dominant advantage in vivo. Cyclosporin A and structurally related compounds can inhibit HCV replication in vitro and in vivo, and resistance has been mapped, in part, to domains II and III of NS5A 15 . To assess the potential for cross-resistance, the sensitivity of inhibition by cyclosporin A of genotype 1a replicons expressing a range of substitutions conferring resistance to BMS-790052 was examined. Cyclosporin A inhibition was not significantly affected by any of the substitutions studied, with EC 50 values comparable to that observed with a wildtype genotype 1a replicon ( Supplementary Table 9 ).
To confirm that NS5A inhibitors bind to the viral protein, we prepared the biotin-tagged derivative 1, with the natural (S)-configuration at both proline stereocentres, and its diastereomer 2 (Fig. 1 ). Compound 1 inhibited subgenomic viral RNA replication in the Con-1 genotype 1b replicon with an EC 50 of 33 nM but was inactive towards a Y93H replicon (EC 50 . 10 mM) whereas the diastereomer 2, used as a control, was inactive in vitro (EC 50 . 10 mM). After exposure to active inhibitor 1, the replicon lysate was passed over streptavidin agarose beads, separated by SDS-polyacrylamide gel electrophoresis and probed with an antibody specific for HCV NS5A, with a parallel experiment using the inactive diastereomer 2 serving as a control. NS5A could only be pulled down efficiently with active inhibitor 1 but not by the inactive compound 2 (Fig. 2 ); NS3 and NS5B were not detected in pull-down experiments with 1, suggesting selective binding to NS5A. In a similar experiment conducted with replicons expressing BVDV RNA, compound 1 failed to bind to BVDV NS5A.
HCV NS5A is a 447 amino-acid, zinc-binding phosphoprotein that plays a critically important but enigmatic role in the virus life cycle 16 . The substitutions conferring resistance to BMS-790052 map to domain I of the protein, which incorporates an amphipathic amino (N)-terminal a-helix (residues 5-25) thought to anchor the protein to the membrane 16 . The solid-state structure of fragments of domain I (residues 36-198 and 33-191) of HCV NS5A reveal dimeric complexes with patterns of interfacial recognition that anticipate an oligomeric form of the protein 17, 18 , postulated to sequester RNA within the replication complex 19 . The unique palindromic topology of BMS-790052 complements the dimeric structure of the NS5A protein. The location of the resistant substitutions suggests that the compound binds across the dimer interface, proximal to the N terminus of domain I between the protein and the membrane, and on the face opposite that of the putative RNA binding domain. We speculate that BMS-790052 may interfere with the precision of dimer association, effecting subtle structural distortions that directly or allosterically interfere with protein function. Under these circumstances, the exquisite inhibitory potency exhibited by BMS-790052 in vitro may be related to the disruption of the function of a limited number of NS5A dimers that compromise the activity of an oligomeric complex. However, although this hypothesis allows for an amplification of inhibitory effect, an alternative explanation relies on the inhibition of two or more activities of NS5A that interact synergistically. Further studies with BMS-790052 will be required to define its exact mode of action more fully and, conversely, the compound is a useful tool with which to study aspects of HCV NS5A function in viral replication. These investigations may be aided by compounds with an in vitro profile similar to 1, which is restricted to genotype 1b inhibition 10 .
BMS-790052 exhibited no significant effects in an extensive battery of in vitro receptor binding and enzymatic assays designed to assess promiscuity. Despite a molecular mass of over 700 daltons, the compound is orally bioavailable in four preclinical species, with plasma levels readily achieved that surpass the in vitro EC 50 , and it distributes effectively to the liver.
In a randomized, double-blind, placebo-controlled, single ascendingdose study, BMS-790052 was administered at six dose levels to healthy, non-HCV-infected subjects over a range of 1 to 200 mg as an oral solution. The compound was safe and well tolerated up to 200 mg with LETTERS no clinically relevant adverse effects. After oral administration, BMS-790052 was readily absorbed, with dose-proportional exposures over the studied dose range, and all subjects had drug concentrations greater than the protein-binding-adjusted EC 90 for genotypes 1a and 1b, as measured in the replicon assay, at and beyond 24 h post-dose ( Fig. 3 ). (The protein binding-adjusted EC 90 figures were derived from an analysis of the effect of the addition of human serum on antiviral activity in replicons. In the presence of 40% human serum, the EC 90 for BMS-790052 is 383 pM (0.28 ng ml 21 ) for the genotype 1a replicon and 49 pM (0.04 ng ml 21 ) for the genotyope 1b replicon.) In a randomized, double-blind, placebo-controlled, single ascendingdose study, BMS-790052 was administered to subjects with genotype 1 chronic HCV at doses of 1, 10 and 100 mg as an oral solution. All subjects were infected with HCV genotype 1a except for two subjects at 10 mg and three subjects at 100 mg who were infected with genotype 1b. BMS-790052 was safe and well tolerated in HCV-infected subjects after single oral doses up to 100 mg. Specifically, there were no deaths, serious adverse events, discontinuations due to adverse events or clinically relevant adverse effects. Headache was the most frequent adverse event, reported by four subjects after administration of BMS-790052. In HCV-infected subjects, BMS-790052 had a mean plasma elimination half-life ranging from 10 to 14 h, and plasma drug levels were similar to those in non-HCV-infected subjects. After single oral doses of 10-100 mg BMS-790052, all subjects had 24-h plasma concentrations above the tenfold protein binding-adjusted EC 90 for HCV genotypes 1a and 1b, suggesting the possibility for once daily administration. The plasma HCV RNA levels were measured for up to 6 days after administration; the mean decline from the time of administration to 144 h post-dose is shown in Fig. 4 . A single milligram dose of BMS-790052 produced a mean 1.8 log 10 reduction (range 0.2-3.0 log 10 ) in HCV viral load measured 24 h after drug administration. Both the 10 and 100 mg doses produced a greater antiviral effect, with mean plasma viral RNA falling by 3.2 log 10 (range 2.9-4.0 log 10 ) and 3.3 log 10 (range 2.7-3.6 log 10 ), respectively, at 24 h post-dose. Moreover, the 100 mg dose resulted in a mean maximal HCV RNA decline of 3.6 log 10 (range 3.0-4.1 log 10 ) and a prolonged antiviral response was observed in two subjects infected with genotype 1b virus, with an HCV RNA measurement that reached the lower limit of quantification (less than 25 IU ml 21 ) in one subject and 35 IU ml 21 in the other measured at hour 144. Genotypic analysis of samples taken at baseline (T0), 24 (T24) and 144 (T144) hours post-dose revealed that, in general, a marked reduction in viral load was required to detect major HCV variants. Substitutions were observed at aminoacid positions identified using the in vitro replicon system (Supplementary Tables 12-14) : M28T, Q30H/R and L31M for genotype 1a, and Y93H for genotype 1b, results that suggest the usefulness of the replicon system for assessing resistance in response to inhibitor pressure in vivo. Follow-up samples were available for only one of these subjects, which revealed that HCV RNA had returned to near baseline; however, genotype analysis was not performed on this sample. As would be anticipated based on the in vitro replicon potency of BMS-790052, a greater and more sustained decline in HCV RNA was observed for subjects infected with genotype 1b (mean 3.6 log 10 reduction (range 3.1-4.0 log 10 ) and mean 3.1 log 10 reduction (range 2.7-3.4 log 10 ) in HCV viral load measured 24 h after a 10 and 100 mg dose, respectively) than for subjects infected with genotype 1a (mean 1.8 log 10 reduction (range 0.2-3.0 log 10 ), mean 2.9 log 10 reduction (range 2.9-3.0 log 10 ) and mean 3.6 log 10 reduction (range 3.5-3.6 log 10 ) in HCV viral load measured 24 h after a 1, 10 and 100 mg dose, respectively). The mean rates of decline for subjects who received 10 and 100 mg doses of BMS-790052 were similar up to 36 h after dosing, after which the mean decline was greater and more sustained in the subjects who received 100 mg. Subjects who received 1 mg of BMS-790052 had a lower mean decline in HCV RNA than subjects treated with 10 and 100 mg (Fig. 4) . However, multiple-dose studies are needed to define the optimal dose range for maximal antiviral effect beyond the first phase of viral decline. The relationships between maximum decline from baseline in HCV RNA and drug pharmacokinetics exposures were explored using Pearson's correlation coefficients. All estimated Pearson's correlation coefficients were above 0.65, suggesting that the maximum declines in log 10 HCV RNA and log pharmacokinetics exposures (BMS-790052 C max , AUC(0-T), AUC(INF), C12 and C24) were positively correlated; that is, that the maximum declines in log 10 HCV RNA increase with the exposure to BMS-790052.
Individuals infected with HCV are at considerable risk of developing liver cirrhosis, end-stage liver disease and hepatocellular carcinoma 20 . The current standard of care for the treatment of HCV infection is a combination of weekly subcutaneous injections of pegylated interferon-a in conjunction with ribavirin, administered orally twice a day, for periods ranging from 24 to 72 weeks, depending on genotype 2,3 . However, the side effects associated with this therapeutic regimen impose a significant physiological and psychological burden on the patient. Moreover, sustained virological response rates in those infected with genotype 1 are typically less than 50% (refs 2, 3) . The direct-acting HCV antiviral drug candidates currently reported to be in late-stage clinical development are inhibitors of NS3 protease and NS5B polymerase, more traditional antiviral targets. Although these compounds are currently being developed as an add-on therapy to the standard of care, there is considerable anticipation for combinations of direct-acting agents, which will require at least two mechanistically distinct inhibitors to suppress the emergence of resistant virus 4, 21 . The preliminary in vitro and clinical profile of NS5A inhibitors described in this paper makes them a potentially valuable component of any interferon-free treatment regimen. Figure 2 | The active inhibitor 1 binds to genotype 1b HCV NS5A whereas the inactive stereoisomer 2 does not. Genotype 1b replicon cells were exposed to either 1 or 2 for approximately 18 h before the cells were lysed. A portion of the supernatant was set aside to serve as input control for immunoblot analysis (lanes 1 and 2) while the remainder was mixed with streptavidin-agarose beads and incubated for several hours. Bound proteins were detected by immunoblotting with primary antibodies directed to HCV NS5A. Lanes 1 and 3 depict the results of experiments with the active inhibitor compound 1 whereas lanes 2 and 4 depict the results with the inactive stereoisomer 2.
The results with BMS-790052 provide clinical validation for the first in a new class of HCV inhibitors that target a viral protein with no known enzymatic function and an as yet poorly understood role in viral replication 16, 22 . The strategy used to identify a lead HCV NS5A inhibitor and to optimize this molecule into a clinical candidate offers a contemporary demonstration of the effectiveness of an approach to drug discovery based on chemical genetics 6 . Indeed, this methodology is uniquely applicable to targets similar to HCV NS5A for which precise function is enigmatic and the development of biochemical assays could neither be anticipated nor are feasible. As a specific inhibitor of HCV, BMS-790052 exhibits a spectrum of genotype inhibition, in vitro potency, and efficacy and potency after single oral doses to chronically HCV-infected subjects that is collectively and individually unprecedented. Achieving high potency and selectivity against a non-mammalian target, the traditional goal of antiviral medicinal chemistry, has in the past translated into a wider therapeutic index in the clinic. Although preliminary, these data indicate that inhibitors of HCV NS5A offer considerable promise for the treatment of HCV infection. The in vitro data demonstrating additive to synergistic interactions with known HCV inhibitors In a double-blind, placebo-controlled, sequential, single ascending-dose study, six subjects were randomized within each dose panel (1, 10, 100 mg) to drug or placebo in a ratio of 5:1. BMS-790052 or placebo was administered in the fasted state. Owing to a dosing error, all six subjects received BMS-790052 in the 1 mg panel. One subject in the 10 mg panel withdrew from the study 8 h after administration of the study drug for nondrug-related reasons; HCV RNA data from the subject are included up until the subject withdrew. 200 mg (n = 6) 100 mg (n = 6) 50 mg (n = 6) 25 mg (n = 6) 10 mg (n = 6) 1 mg (n = 6) PBA EC 90 in replicon (0.28 ng ml -1 )-genotype 1a PBA EC 90 in replicon (0.04 ng ml -1 )-genotype 1b suggest that combinations of BMS-790052, with either current standard of care or, ultimately, emerging inhibitors of HCV NS3 and NS5B as part of a cocktail of direct-acting antiviral agents, may lead to therapeutic regimens with better tolerability and improved clinical outcomes 21 .
METHODS SUMMARY
In vitro HCV replicon systems. Construction and isolation of HCV replicons, including hybrid replicons for genotype coverage and replicon assays, have been described previously and are elaborated in the Supplementary Information 9,10 . For the genotype 1a replicon, the P1496L substitution in the NS3 gene and the S2204I substitution in the NS5A gene were used as the adaptive substitutions for efficient replicon replication. For the genotype 1b replicon, a S2204I substitution in the NS5A gene was used as the adaptive mutation. HCV-infected clinical study population. In total, 16 subjects received treatment with BMS-790052 and two subjects received placebo. Subjects selected for this study included men and women aged 18-49 years, inclusive, who were chronically infected with HCV genotype 1 and were treatment naive or treatment non-responders, defined as subjects who received the current standard of care (interferon and/or ribavirin) and who continued to have a detectable HCV RNA level (including relapsers) or subjects who did not attain a 2 log 10 decline in HCV RNA levels at 12 weeks and stopped treatment; or treatment-intolerant subjects, defined as subjects who were unable to tolerate the toxicities associated with interferon and/or ribavirin; and who had not received another NS5A replication co-factor inhibitor; and who were not co-infected with human immunodeficiency virus, hepatitis B virus or HCV other than genotype 1.
Eligible subjects also had an HCV RNA viral load of at least 10 5 IU ml 21 , a documented FibroSure score of not more than 0.59, an aspartate aminotransferase to platelet ratio index of not more than 2 and a body mass index of 18-35 kg m 22 , inclusive. All subjects signed the informed consent form, and were screened and determined to be eligible based on medical history, physical examination and measurements, vital signs, a 12-lead electrocardiogram, and clinical laboratory measurements including serology.
